Christopher J. Melani, MD, discusses updated data from the phase 1b/2 ViPOR trial of the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, in patients with diffuse large B-cell lymphoma.
Christopher J. Melani, MD, assistant research physician in the Lymphoid Malignancies Branch at the Center for Cancer Research, National Cancer Institute, discusses updated data from the phase 1b/2 ViPOR trial (NCT03223610) of the combination of venetoclax (Venclexta), ibrutinib (Imbruvica), prednisone, obinutuzumab (Gazyva), and lenalidomide (Revlimid), in patients with diffuse large B-cell lymphoma (DLBCL).
According to Melani, the combination, which is given in short, non-continuous cycles, showed promising safety and efficacy results and was well-tolerated across all ages. A total of 38% of patients achieved complete remission (CR), and these rates were even higher in certain subtypes.
While further research is needed, the ViPOR study represents a potentially transformative approach for patients with DLBCL.
Transcription:
0:10 | I presented data for the relapsed/refractory cohort of the ViPOR study. ViPOR is a novel combination targeted therapy regimen building on some of the synergy that we've seen in preclinical studies of DLBCL, combining several agents that target B-cell receptor signaling, such as ibrutinib, prednisone, as well as lenalidomide, in addition to venetoclax, which targets BCL2 and apoptosis, and obinutuzumab which facilitates innate immunity through CD20. It really is a novel concept because it's modeled after cytotoxic chemotherapy, where all of the targeted agents are given in non continuous cycles, so 2 weeks of study drug, 1 week break for a fixed duration. So only 6 cycles or 18 weeks without any maintenance therapy.
0:53 | What was impressive regarding this regimen is 1: it was extremely safe and tolerable for patients of all ages, even upwards into their 80s, compared [with] other types of regimens such as cytotoxic chemotherapy, and it was very effective.
1:10 | Overall the rate of complete remission was 38% in patients with relapsed/refractory large cell [lymphoma], with a median line of therapy of 3. In some subtypes, such as the ABC or non GCB subtype of diffuse large B-cell lymphoma, as well as high grade B-cell lymphoma double-hit BCL2, the CR rates were in the 62% and 53% range, respectively. Despite the time-limited therapy of only 6 cycles, these remissions were very durable. Overall, our 2-year progression-free survival was 34%. In double-hit, it was 47%, and in high-grade B-cell lymphoma, it was 38% and a median follow-up of 40 months. These were very deep and durable remissions, despite a very fixed limited therapy.
Glofitamab/Chemo Leads to Survival Benefit in Transplant-Ineligible R/R DLBCL
July 3rd 2024A study found that glofitamab plus gemcitabine and oxaliplatin significantly improved survival in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for stem cell transplant.
Read More
CAR T-Cell Therapy Presents a Paradigm Changing Option in DLBCL
May 23rd 2024During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed how the burgeoning use of chimeric antigen receptor T-cell therapy presents a paradigm shift in treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Alencar Discusses Treatment Choices After Early Relapse of DLBCL
May 18th 2024During a Case-Based Roundtable® event, Alvaro Jose Alencar, MD, moderated a peer discussion on treatment options for a patient with diffuse large B-cell lymphoma whose disease relapsed eight months after completion of standard R-CHOP.
Read More
Peers Discuss Role of Pola-R-CHP vs R-CHOP in Newly Diagnosed DLBCL
April 19th 2024During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More